Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1758835918780140 http://scihub22266oqcxt.onion/10.1177/1758835918780140 C6024329!6024329 !29977352     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29977352 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29977352 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Ther+Adv+Med+Oncol 2018 ; 10 (ä): 1758835918780140 Nephropedia Template TP {{tp|p=29977352 |t=2018. 5-fluorouracil and cardiotoxicity: a review |pdf=|usr=}}{{29977352 }} gab.com Text 5-fluorouracil and cardiotoxicity: a review JO: Ther Adv Med Oncol http://www.kidney.de/pget.php?&tw=1&pmid=29977352 #FOAvip Fluoropyrimidines such as 5-fluorouracil (5-FU) form the foundation of a wide variety of chemotherapy regimens. 5-FU is in fact the third most commonly used chemotherapeutic agent in the treatment of solid malignancies across the world. As with all chemotherapy, balancing the potential benefits of therapy against the risks of drug-related toxicity is crucial when clinicians and patients make shared decisions about treatment. 5-FU is the second most common chemotherapeutic drug associated with cardiotoxicity after anthracyclines, which can manifest as chest pain, acute coronary syndrome/myocardial infarction or death. Nevertheless a widespread appreciation of 5-FU-related cardiotoxicity and its implications is lacking amongst clinicians. In this review, we outline the incidence, possible risk factors, and likely pathophysiological mechanisms that may account for 5-FU-related cardiotoxicity and also highlight potential management strategies for this poorly understood clinical entity. Twit Text FOAVip 5-fluorouracil and cardiotoxicity: a review ????Ther Adv Med Oncol http://www.kidney.de/pget.php?&tw=1&pmid=29977352 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29977352 #FOAvip English Wikipedia <ref>{{Cite pmid|29977352 }}</ref> 5-fluorouracil and cardiotoxicity: a review #MMPMID29977352 Sara JD ; Kaur J ; Khodadadi R ; Rehman M ; Lobo R ; Chakrabarti S ; Herrmann J ; Lerman A ; Grothey A Ther Adv Med Oncol 2018[]; 10 (ä): 1758835918780140 PMID29977352 show ga Fluoropyrimidines such as 5-fluorouracil (5-FU) form the foundation of a wide variety of chemotherapy regimens. 5-FU is in fact the third most commonly used chemotherapeutic agent in the treatment of solid malignancies across the world. As with all chemotherapy, balancing the potential benefits of therapy against the risks of drug-related toxicity is crucial when clinicians and patients make shared decisions about treatment. 5-FU is the second most common chemotherapeutic drug associated with cardiotoxicity after anthracyclines, which can manifest as chest pain, acute coronary syndrome/myocardial infarction or death. Nevertheless a widespread appreciation of 5-FU-related cardiotoxicity and its implications is lacking amongst clinicians. In this review, we outline the incidence, possible risk factors, and likely pathophysiological mechanisms that may account for 5-FU-related cardiotoxicity and also highlight potential management strategies for this poorly understood clinical entity. ä5-fluorouracil and cardiotoxicity: a review (epmc).pdf DeepDyve Pubget Overpricing